A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Latest Information Update: 22 May 2025
At a glance
- Drugs Aficamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Registrational; Therapeutic Use
- Acronyms SEQUOIA-HCM
- Sponsors Cytokinetics
Most Recent Events
- 18 May 2025 According to a Cytokinetics media release,additional data arising from two analyses from this study were presented at the European Society of Cardiology Heart Failure 2025 Congress.
- 18 May 2025 Results presented in the Cytokinetics, Incorporated Media Release
- 17 Mar 2025 Results presented in the Cytokinetics Media Release.